CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

Randomized, Multi-Centric, Double-Blind Comparative Study To Evaluate Efficacy And Safety Of Biosimilar Pegfilgrastim And Reference Pegfilgastrim In Patients With Chemotherapy Induced Neutropenia (Cin)

Author: 
Prasad Apsangikar, Manoj Naik, Sunil Chaudhry, Shashank Deosghare, Jamila Joseph
Subject Area: 
Life Sciences
Abstract: 

Background: Pegfilgrastim is the most widely used long-acting G-CSF available worldwide in the management of febrile neutropenia during chemotherapy. Objective: The present multicentre study evaluated efficacy and safety of pegfilgrastim biosimilar against innovator reference pegfilgrastim, when given subcutaneously in patients with Chemotherapy Induced Neutropenia (CIN). Methods: A prospective, multi-centre, randomized, double-blind, two-arm, parallel group, active-control, comparative clinical study to evaluate efficacy and safety of biosimilar pegfilgrastim (study arm)/ innovator pegfilgrastim (reference arm) in patients with Chemotherapy Induced Neutropenia. A total of 105 patients were enrolled in in two arms i.e. study pegfilgrastim and innovator pegfilgrastim. The primary objective of the study was to evaluate the duration of Grade 4 neutropenia in patients receiving study drug / reference drug in the 1st cycle of chemotherapy during the study and the secondary objectives of the study were to study the incidence of Grade 4 neutropenia, the incidence and duration of febrile neutropenia, time to ANC recovery after ANC nadir and the depth of ANC nadir in Cycles 1 to 4. Results: Mean duration of Grade 4 neutropenia was 1.43 days in the study arm and 2.00 days in the reference arm. In the secondary efficacy analysis, most cases of Grade 4 neutropenia occurred in the first cycle. No cases of Grade 4 neutropenia were noted during cycle 2 in either of the treatment arms. The incidence of Grade 4 neutropenia in the study arm was 4.76% in cycle 3 and 1.11% in cycle 4. The incidence of Grade 4 neutropenia in the reference arm was 6.25% in cycle 3. There was no statistically significantly difference between the study and reference arm during cycle 3.(P= 0.759). No subject in either arm developed febrile neutropenia in any of the cycles other than this sporadic case. The depth of ANC nadir in study arm was lowest in cycle 1, (2.914 x109/L) and in reference arm, the depth of ANC nadir was lowest in cycle 4 (3.23 x109/L). The mean time to ANC recovery (≥2.0x109/L) after the ANC nadir in study arm and in reference arm was comparable. Observed difference between two arms in 2nd, 3rd, and 4th cycle was statistically insignificant. Conclusion: The biosimilar pegfilgrastim was found to be as effective and safe as reference pegfilgrastim product. The analysis of secondary endpoints were consistent with those of the primary endpoint, with reduction in incidence and duration of grade 4 neutropenia and febrile neutropenia.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran